GastroenterologySimplifying Ulcerative Colitis Treatment: Evaluating a Single 1600 mg 5-ASA Tablet Regimen in the EASI Trial
MedXY Editorial Team
Highlight
- The EASI trial tested whether a single 1600 mg 5-ASA tablet improves adherence in ulcerative colitis compared to three 800 mg tablets.
- Adherence rates were comparable between groups, with a trend toward fewer missed doses in the single-tablet group.
- Relapse rates and symptom control did not differ significantly between regimens during 12 months of use.
- The single 1600 mg tablet is a practical alternative that may simplify treatment without compromising efficacy or safety.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
